Genmab AS (OCSE:GMAB) Days Inventory : 22.74 (As of Mar. 2025)

View and export this data going back to 2000. Start your Free Trial

What is Genmab AS Days Inventory?

Days Inventory is also known as Days Sales of Inventory (DSI). Genmab AS's Average Total Inventories for the three months ended in Mar. 2025 was kr72 Mil. Genmab AS's Cost of Goods Sold for the three months ended in Mar. 2025 was kr290 Mil. Hence, Genmab AS's Days Inventory for the three months ended in Mar. 2025 was 22.74.

The historical rank and industry rank for Genmab AS's Days Inventory or its related term are showing as below:

OCSE:GMAB' s Days Inventory Range Over the Past 10 Years
Min: 22.27 Med: 57.17 Max: 92.06
Current: 25.02

During the past 13 years, Genmab AS's highest Days Inventory was 92.06. The lowest was 22.27. And the median was 57.17.

OCSE:GMAB's Days Inventory is ranked better than
93.77% of 642 companies
in the Biotechnology industry
Industry Median: 180.08 vs OCSE:GMAB: 25.02

Genmab AS's Days Inventory declined from Mar. 2024 (40.16) to Mar. 2025 (22.74).

Inventory Turnover measures how fast the company turns over its inventory within a year. Genmab AS's Inventory Turnover for the three months ended in Mar. 2025 was 4.01.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Genmab AS's Inventory-to-Revenue for the three months ended in Mar. 2025 was 0.01.

Genmab AS Days Inventory Historical Data

The historical data trend for Genmab AS's Days Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genmab AS Days Inventory Chart

Genmab AS Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Days Inventory

Get a 7-Day Free Trial

92.06

22.27

Genmab AS Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Days Inventory	Get a 7-Day Free Trial															40.16	34.02	17.82	21.12	22.74

Competitive Comparison of Genmab AS's Days Inventory

For the Biotechnology subindustry, Genmab AS's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genmab AS's Days Inventory Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genmab AS's Days Inventory distribution charts can be found below:

* The bar in red indicates where Genmab AS's Days Inventory falls into.

Save Embed

;

Save Embed

;

Genmab AS Days Inventory Calculation

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Genmab AS's Days Inventory for the fiscal year that ended in Dec. 2024 is calculated as

	Days Inventory (A: Dec. 2024 )
=	Average Total Inventories					/	Cost of Goods Sold	*	Days in Period
=	( (Total Inventories (A: Dec. 2023 )	+	Total Inventories (A: Dec. 2024 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2024 )	*	Days in Period
=	( (57.843	+	61.606)	/	2 )	/	978.747	*	365
=	59.7245					/	978.747	*	365
=	22.27

Genmab AS's Days Inventory for the quarter that ended in Mar. 2025 is calculated as:

	Days Inventory (Q: Mar. 2025 )
=	Average Total Inventories					/	Cost of Goods Sold	*	Days in Period
=	( (Total Inventories (Q: Dec. 2024 )	+	Total Inventories (Q: Mar. 2025 ))	/	count )	/	Cost of Goods Sold (Q: Mar. 2025 )	*	Days in Period
=	( (61.606	+	82.792)	/	2 )	/	289.771	*	365 / 4
=	72.199					/	289.771	*	365 / 4
=	22.74

Genmab AS (OCSE:GMAB) Days Inventory Explanation

Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:

1. Inventory Turnover measures how fast the company turns over its inventory within a year.

Genmab AS's Inventory Turnover for the three months ended in Mar. 2025 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	289.771	/	72.199
	=	4.01

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Genmab AS's Inventory to Revenue for the three months ended in Mar. 2025 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	72.199	/	4933
	=	0.01

Be Aware

A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.

Genmab AS Days Inventory Related Terms

Thank you for viewing the detailed overview of Genmab AS's Days Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

Genmab AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab AS (OCSE:GMAB) » Definitions » Days Inventory

Comparable Companies

Traded in Other Exchanges

GNMSF:USA GMAB:USA GMABc:UK 0MGB:UK GE91:Germany GE91:Germany GE9:Germany GMAB:Austria

Address

Carl Jacobsens Vej 30, Valby, DNK, 2500

Website

https://www.genmab.com

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.